Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Edward Britton is a corporate senior counsel resident in the firm’s Washington office.  He concentrates in strategic licensing, partnering, and joint ventures; supply, distribution, research, and other commercial agreements; and mergers, acquisitions, and divestitures.  His practice emphasizes multi-jurisdictional transactions, and he has broad experience in the types of issues that such transactions raise.  He also regularly advises clients on corporate and governance issues and assists clients on general compliance matters.

From 2003 to 2008, Mr. Britton was resident in the firm’s London office, where he served as managing partner.

  • Salix Pharmaceuticals in its $2.6 billion acquisition of Nasdaq-listed Santarus, Inc.; in its acquisition of assets from Olon S.p.A.; in its $300 million acquisition of Oceana Therapeutics; in its worldwide collaboration with RedHill Biopharma for purgative technology; in its acquisition of worldwide rights to the Relistor® product from Progenics Pharmaceuticals; in its worldwide collaboration with Photocure ASA for the development and commercialization of a photodynamic diagnostic technology; in settlements of Hatch-Waxman litigation against Lupin, Novel Laboratories and Actavis; in its collaboration with Lupin in respect of rifaximin-containing products; in its worldwide collaboration with Napo Pharmaceuticals for the development and commercialization of crofelemer as an anti-diarrhetic, together with a related equity investment by Salix in Napo, and a related manufacture and supply agreement between Salix and Glenmark Pharmaceuticals; and in respect of numerous supply, manufacturing, clinical trial, services, and other agreements.
  • Boehringer Ingelheim in its $880 million sale of Fort Dodge and related divestures of animal health products.
  • Medarex in global collaborations with Epicyte Pharmaceuticals and Immusol to research, develop, manufacture and commercialize monoclonal antibody products.
  • Chiron in an in-license from Coley Pharmaceutical Group.
  • Seragen, a Nasdaq-listed biotech, in the restructuring of its Canadian affiliate Seragen Biopharmaceuticals Ltd., the sale of certain company assets to Marathon Biopharmaceuticals, and its acquisition by Ligand Pharmaceuticals.
  • UCB in its pending $2.1 billion acquisition of Ra Pharmaceuticals, its $1.2 billion sale of Kremers Urban Pharmaceuticals to Lannett, and its acquisition of midazolam nasal spray from Proximagen.  
  • Zycos in multiple venture capital financings, commercial transactions, and its sale to MGI Pharma. 
  • Eisai in the reorganization of its North American affiliates.
  • Boehringer-Ingelheim in the reorganization of its North American operations.
  • Michel Baulé S.A. in its joint venture with Bayer Material Science AG in the field of hot and cold cast elastomers.
  • HealthPoint Capital Partners in an investment in Scient’X S.A., a French medical device company.
  • AstraZeneca in its equity investments in Abgenix and CancerVax.
  • Bacardi Limited in its acquisition of the St-Germain liqueuer brand; in its investment in Patrón Spirits International A.G; in its joint venture with Anheuser-Busch for the Bacardi Silver product; in its bid for the drinks assets of Seagram; in its acquisition of the Dewars, Bombay, and Bombay Sapphire brands from Diageo; and in its acquisition of the Martini & Rossi companies.
  • James C. Bradford, Jr., as a principal member of J.C. Bradford & Co., a leading stock broking firm in the southeastern United States, in the acquisition of J.C. Bradford & Co. by PaineWebber.
  • Aegis Research Corporation, a privately held government contractor providing services to the US defense and intelligence communities, in its sale to ManTech International.
  • Decision Systems Technologies, a privately held defense contractor, in its sale to STG, Inc.
  • Dunlop Slazenger Group in its sale of the Maxfli golf brand and related assets to Taylor Made Golf Company and its license to a US-based private equity group of the “Slazenger” golf brand for North America.

Pro Bono

  • Representation in parole hearings of District of Columbia prisoners.
  • Legal counsel to the Protestant Episcopal Cathedral Foundation of the District of Columbia.

Previous Experience

  • U.S. House of Representatives, Congressman James P. Johnson, Legislative Assistant